ID   NIPI3_CAEEL             Reviewed;         655 AA.
AC   G5EED4;
DT   22-JUL-2015, integrated into UniProtKB/Swiss-Prot.
DT   14-DEC-2011, sequence version 1.
DT   18-JUN-2025, entry version 87.
DE   RecName: Full=Protein nipi-3 {ECO:0000305};
DE   AltName: Full=No induction of peptide after drechmeria infection protein 3 {ECO:0000312|WormBase:K09A9.1};
DE   AltName: Full=Tribbles homolog nipi-3 {ECO:0000303|PubMed:27927200, ECO:0000303|PubMed:27927209, ECO:0000303|PubMed:34407394};
GN   Name=nipi-3 {ECO:0000312|WormBase:K09A9.1};
GN   ORFNames=K09A9.1 {ECO:0000312|WormBase:K09A9.1};
OS   Caenorhabditis elegans.
OC   Eukaryota; Metazoa; Ecdysozoa; Nematoda; Chromadorea; Rhabditida;
OC   Rhabditina; Rhabditomorpha; Rhabditoidea; Rhabditidae; Peloderinae;
OC   Caenorhabditis.
OX   NCBI_TaxID=6239 {ECO:0000312|Proteomes:UP000001940};
RN   [1] {ECO:0000312|EMBL:ABW05091.1}
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, DEVELOPMENTAL
RP   STAGE, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF ILE-307.
RX   PubMed=18394898; DOI=10.1016/j.cub.2008.02.079;
RA   Pujol N., Cypowyj S., Ziegler K., Millet A., Astrain A., Goncharov A.,
RA   Jin Y., Chisholm A.D., Ewbank J.J.;
RT   "Distinct innate immune responses to infection and wounding in the C.
RT   elegans epidermis.";
RL   Curr. Biol. 18:481-489(2008).
RN   [2] {ECO:0000312|Proteomes:UP000001940}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Bristol N2 {ECO:0000312|Proteomes:UP000001940};
RX   PubMed=9851916; DOI=10.1126/science.282.5396.2012;
RG   The C. elegans sequencing consortium;
RT   "Genome sequence of the nematode C. elegans: a platform for investigating
RT   biology.";
RL   Science 282:2012-2018(1998).
RN   [3]
RP   FUNCTION, INTERACTION WITH CEBP-1, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND DISRUPTION PHENOTYPE.
RX   PubMed=27927209; DOI=10.1186/s12915-016-0320-z;
RA   Kim K.W., Thakur N., Piggott C.A., Omi S., Polanowska J., Jin Y., Pujol N.;
RT   "Coordinated inhibition of C/EBP by Tribbles in multiple tissues is
RT   essential for Caenorhabditis elegans development.";
RL   BMC Biol. 14:104-104(2016).
RN   [4]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF ILE-307.
RX   PubMed=27927200; DOI=10.1186/s12915-016-0334-6;
RA   McEwan D.L., Feinbaum R.L., Stroustrup N., Haas W., Conery A.L.,
RA   Anselmo A., Sadreyev R., Ausubel F.M.;
RT   "Tribbles ortholog NIPI-3 and bZIP transcription factor CEBP-1 regulate a
RT   Caenorhabditis elegans intestinal immune surveillance pathway.";
RL   BMC Biol. 14:105-105(2016).
RN   [5]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND MUTAGENESIS OF ILE-307.
RX   PubMed=34407394; DOI=10.1016/j.celrep.2021.109529;
RA   Wu C., Karakuzu O., Garsin D.A.;
RT   "Tribbles pseudokinase NIPI-3 regulates intestinal immunity in
RT   Caenorhabditis elegans by controlling SKN-1/Nrf activity.";
RL   Cell Rep. 36:109529-109529(2021).
CC   -!- FUNCTION: Adapter protein that regulates different signaling pathways
CC       (By similarity). Required for larval development and viability
CC       (PubMed:27927209). Involved in negatively modulating pmk-1 p38/MAPK
CC       signaling (PubMed:27927209). Involved in innate immunity, acting either
CC       in a manner dependent upon, or independent of, the pmk-1 or pmk-3
CC       p38/MAPK pathways (PubMed:18394898, PubMed:27927200, PubMed:34407394).
CC       Has a protective role in response to infection by the Gram-negative
CC       bacterium P.aeruginosa, acting by negatively modulating expression of
CC       cebp-1, and regulating the pmk-1 p38/MAPK pathway, leading to
CC       activation of transcription factor skn-1 (PubMed:27927200,
CC       PubMed:34407394). Required to prevent P.aeruginosa toxin ToxA-mediated
CC       lethality, probably acting via modulating the effects of translational
CC       inhibition caused by the toxin (PubMed:27927200). By regulating the up-
CC       regulation in the epidermis of antimicrobial peptides nlp-29 and nlp-
CC       31, plays a role in resistance to fungal infection (PubMed:18394898,
CC       PubMed:27927200). {ECO:0000250|UniProtKB:Q9V3Z1,
CC       ECO:0000269|PubMed:18394898, ECO:0000269|PubMed:27927200,
CC       ECO:0000269|PubMed:27927209, ECO:0000269|PubMed:34407394}.
CC   -!- SUBUNIT: May interact with transcription factor cebp-1 (via N-
CC       terminus). {ECO:0000269|PubMed:27927209}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:27927209}.
CC   -!- TISSUE SPECIFICITY: Expressed in epidermis, pharynx, intestine, a
CC       subset of head neurons and motoneurons. {ECO:0000269|PubMed:18394898,
CC       ECO:0000269|PubMed:27927209}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in the 3-fold stage embryo.
CC       {ECO:0000269|PubMed:18394898}.
CC   -!- DOMAIN: The protein kinase domain is predicted to be catalytically
CC       inactive. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- DISRUPTION PHENOTYPE: Arrested development at the second to third
CC       larval stages (L2-L3) and lethality between 5-10 days after hatching
CC       (PubMed:27927209). Small and dumpy body morphology at the second to
CC       third larval stages (L2-L3), abnormal pharyngeal morphology, sterility
CC       (PubMed:27927209). Growth and fertility defects are suppressed in a
CC       cebp-1 mutant background (PubMed:27927209). Lethality is suppressed in
CC       several mutant backgrounds, including tir-1, or kinases nsy-1, sek-1 or
CC       mak-2 (PubMed:27927209). Levels of phosphorylated, active p38/MAPK pmk-
CC       1 are significantly increased (PubMed:27927209). Increased levels of
CC       cebp-1 mRNA in multiple tissues (PubMed:27927209). RNAi-mediated
CC       knockdown results in a loss of nlp-29 expression upon fungal infection
CC       (PubMed:18394898). No other obvious phenotype (PubMed:18394898).
CC       Knockdown results in a drastic reduction in transcription of gst-4 and
CC       gcs-1 mRNAs during infection by P.aeruginosa or P.faecalis, or
CC       treatment with the oxidant, arsenite (PubMed:34407394). RNAi-mediated
CC       knockdown targeted to intestinal cells causes hypersusceptibility to
CC       Gram-negative bacterium P.aeruginosa or to Gram-positive bacterium
CC       E.faecalis and also to the P.aeruginosa toxin ToxA (PubMed:27927200,
CC       PubMed:34407394). Simultaneous knockdown with vhp-1, targeted to
CC       intestinal cells, results in partial rescue of the nipi-3 pathogen
CC       sensitivity phenotype (PubMed:34407394). {ECO:0000269|PubMed:18394898,
CC       ECO:0000269|PubMed:27927200, ECO:0000269|PubMed:27927209,
CC       ECO:0000269|PubMed:34407394}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; EU043523; ABW05091.1; -; mRNA.
DR   EMBL; BX284606; CAB01883.3; -; Genomic_DNA.
DR   RefSeq; NP_510573.3; NM_078172.10.
DR   AlphaFoldDB; G5EED4; -.
DR   SMR; G5EED4; -.
DR   FunCoup; G5EED4; 372.
DR   STRING; 6239.K09A9.1.1; -.
DR   PaxDb; 6239-K09A9.1; -.
DR   EnsemblMetazoa; K09A9.1.1; K09A9.1.1; WBGene00010700.
DR   GeneID; 181650; -.
DR   KEGG; cel:CELE_K09A9.1; -.
DR   AGR; WB:WBGene00010700; -.
DR   CTD; 181650; -.
DR   WormBase; K09A9.1; CE42581; WBGene00010700; nipi-3.
DR   eggNOG; ENOG502TG0H; Eukaryota.
DR   HOGENOM; CLU_422256_0_0_1; -.
DR   InParanoid; G5EED4; -.
DR   OMA; GKYPFHE; -.
DR   OrthoDB; 410920at2759; -.
DR   PhylomeDB; G5EED4; -.
DR   Reactome; R-CEL-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-CEL-165158; Activation of AKT2.
DR   Reactome; R-CEL-199418; Negative regulation of the PI3K/AKT network.
DR   Reactome; R-CEL-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-CEL-5218920; VEGFR2 mediated vascular permeability.
DR   PRO; PR:G5EED4; -.
DR   Proteomes; UP000001940; Chromosome X.
DR   Bgee; WBGene00010700; Expressed in pharyngeal muscle cell (C elegans) and 4 other cell types or tissues.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; IEA:InterPro.
DR   GO; GO:0061760; P:antifungal innate immune response; IMP:WormBase.
DR   GO; GO:0050832; P:defense response to fungus; IMP:UniProtKB.
DR   GO; GO:0050829; P:defense response to Gram-negative bacterium; IMP:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IMP:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0010468; P:regulation of gene expression; IMP:UniProtKB.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR024104; Tribbles/Ser_Thr_kinase_40.
DR   PANTHER; PTHR22961; SER/THR PROTEIN KINASE-TRB; 1.
DR   PANTHER; PTHR22961:SF13; TRIBBLES; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Nucleotide-binding; Nucleus; Reference proteome.
FT   CHAIN           1..655
FT                   /note="Protein nipi-3"
FT                   /evidence="ECO:0000305"
FT                   /id="PRO_0000433603"
FT   DOMAIN          200..470
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..35
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        21..35
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         206..214
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         235
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MUTAGEN         307
FT                   /note="I->N: In fr4; Susceptibility to fungal infection
FT                   characterized by a severe loss of nlp-29 and nlp-31
FT                   expression and a decrease in survival. Susceptibility to
FT                   bacterial pathogens P.aeruginosa or E.faecalis is
FT                   characterized by a decrease in survival rate; this
FT                   phenotype is abrogated in a cebp-1 mutant background.
FT                   Drastic reduction in transcription of gst-4 and gcs-1 mRNAs
FT                   during infection by P.aeruginosa or P.faecalis; this
FT                   phenotype is abrogated in a cebp-1 mutant background.
FT                   Increased level of vhp-1 mRNA during P.aeruginosa or
FT                   E.faecalis infection. Level of pmk-1 phosphorylation
FT                   reduced during E.faecalis infection, despite almost normal
FT                   overall level of pmk-1 protein. Animals have a
FT                   temperature-sensitive reduction in size. In absence of
FT                   infection, reduced survival rate. Dramatically reduced
FT                   lifespan in response to ToxA from Gram-negative bacterium
FT                   P.aeruginosa. Reduced viability in response to
FT                   translational inhibitor, G418."
FT                   /evidence="ECO:0000269|PubMed:18394898,
FT                   ECO:0000269|PubMed:27927200, ECO:0000269|PubMed:34407394"
SQ   SEQUENCE   655 AA;  75748 MW;  8A19F1933A9F59AA CRC64;
     MARTKCKTKT VANPRTGVRK TAKDLSEPVR QDAVSRRRPT TLPFVGNTSS RPRVFYDVLA
     KKNVVFPNVK AEYHYRVRNA PKIDPKNFGT TLPICYSSIG PAKTLELRPL GRLPPHIIKA
     LNDHYVQLTR GSMVPAADLY NNGDHPAEQR IPTMLNENEY LRLIQELEEE EKSKQFSATS
     SSAPHVNPYS AQHLVNGEII GIFVIYGTGL VTRAVCSQTR EMFTAHVLPE WKASKVIDVI
     RRLQIPTDIS SMTADEIRLS ELCISKRMEI IKSNDRYILM NPCESATIHS YATERLDEIT
     ENDVMSIYQK VVEIVRFCHS RKVILQNFKP RSFYLKKDAH NKWVVRPCFL QDMSCEEDQS
     EAQFTRRSVC VPFMAPEMLT AESRTHHSYS TELWGLGVLL YILLTGKYPF HENSMPLLFR
     TIKFKQHRWP FNFISSKSRN IVNMLLKKAP ATRMNLEDLW NQVNGDFPEI RCRSNIILKK
     QDMIVKMDLF EMYYNTYKDR LLPKNVLPMY EEMKACRNDS TILTEMAKRD FRSIQEQMKR
     RIETKPTEYQ TLVMQVRLQQ INQLFFEKEV SQAQKQHRAP RLVQLKCSDI SKELLLPGDI
     YPISEHYHPS QQPVDKVVYK LLSDANSLAF PTVMKGTVPK SYPPPVFKGL DISPS
//
